Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:24:39 EDT Thu 03 Jul 2025
Enter Symbol
or Name
USA
CA



Q:FDMT - 4D MOLECULAR THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FDMT - Q5.03.90·4.530.24.24-0.07-1.6196.37581,1794.31  4.34  4.1328.9269  2.23516:47:14Jul 0215 min RT 2¢

Recent Trades - Last 10 of 1179
Time ETExPriceChangeVolume
16:47:14Q4.20-0.111,000
15:54:57Q4.380.073
15:33:09Q4.1101-0.199969
14:16:28Q4.380.071
13:30:34Q4.380.072
13:27:46Q4.380.0721
13:11:31Q4.330.0250
13:04:14Q4.24-0.071
13:04:12Q4.24-0.071
13:04:11Q4.24-0.071

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-02 16:05U:FDMTNews Release4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
2025-05-28 08:01U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences
2025-05-16 16:05U:FDMTNews Release4DMT Announces New Employment Inducement Grants
2025-05-08 16:05U:FDMTNews Release4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
2025-05-05 08:00U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences
2025-05-01 08:01U:FDMTNews Release4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
2025-04-11 16:05U:FDMTNews Release4DMT Announces New Employment Inducement Grants
2025-03-27 08:00U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences
2025-03-10 08:00U:FDMTNews Release4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
2025-02-28 16:05U:FDMTNews Release4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
2025-02-19 08:01U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences
2025-02-08 14:30U:FDMTNews Release4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program
2025-01-29 08:00U:FDMTNews Release4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
2025-01-10 08:00U:FDMTNews Release4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
2025-01-10 08:00U:FDMTNews Release4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
2024-12-16 08:00U:FDMTNews Release4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS
2024-11-14 08:00U:FDMTNews Release4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
2024-11-13 16:05U:FDMTNews Release4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
2024-09-23 08:00U:FDMTNews Release4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
2024-09-18 16:05U:FDMTNews Release4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day